Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic stem cell transplantation for chronic myeloid leukemia with inadequate hematologic response to TKIs
2014-003126-40Phase 3Completed
- Sponsor
- University of Milano-Bicocca
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bosutinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by University of Milano-Bicocca. Primary endpoint: Complete Cytogenetic Response at 12 months post transplant. Started May 2015; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2014-003126-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003126-40.